Pliant Therapeutics (PLRX) EBITDA Margin (2020 - 2023)
Pliant Therapeutics (PLRX) posted quarterly EBITDA Margin of 19083.87% for Q2 2023, down 1848972.0% year-over-year from N/an in Q2 2022, and down 503.87% quarter-over-quarter from 3160.29% in Q1 2023.
Pliant Therapeutics (PLRX) EBITDA Margin (2020 - 2023) Analysis & Trends
Pliant Therapeutics (PLRX) has reported EBITDA Margin for 4 consecutive years, with 19083.87% the latest figure, recorded in Q2 2023.
- In Q2 2023, EBITDA Margin fell 1848972.0% year-over-year to 19083.87%; the TTM figure through Mar 2024 stood at 78404.03% (down 7695968.0% YoY), while the FY2023 annual figure was 11654.75%, down 1034138.0% from the prior year.
- EBITDA Margin declined to 19083.87% in Q2 2023 per PLRX's latest filing, from 3160.29% in the prior quarter.
- Across five years, EBITDA Margin topped out at 38.04% in Q1 2020 and bottomed at 19083.87% in Q2 2023.
- Historically, EBITDA Margin has averaged 2543.94% across 4 years, with a median of 1255.42% in 2021.
- Annual changes were most pronounced in 2022 — EBITDA Margin soared 68612 bps — and 2023, when it tumbled 1848972 bps.
- Pliant Therapeutics' EBITDA Margin stood at 430.52% in 2020, then tumbled by 186 bps to 1230.57% in 2021, then tumbled by 55 bps to 1903.31% in 2022, then sank by 903 bps to 19083.87% in 2023.
- Business Quant data shows PLRX's EBITDA Margin at 19083.87% in Q2 2023, 3160.29% in Q1 2023, and 1903.31% in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 17.93% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.36% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.75% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -35.57% |
| 10 | Pliant Therapeutics | 70.59 Mn | 70.59 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | -19,083.87% |
| Mar 31, 2023 | -3,160.29% |
| Dec 31, 2022 | -1,903.31% |
| Sep 30, 2022 | -2,155.67% |
| Jun 30, 2022 | -594.15% |
| Mar 31, 2022 | -2,258.69% |
| Dec 31, 2021 | -1,230.57% |
| Sep 30, 2021 | -1,684.04% |
| Jun 30, 2021 | -1,280.27% |
| Mar 31, 2021 | -1,054.23% |
| Dec 31, 2020 | -430.52% |
| Sep 30, 2020 | -346.09% |
| Jun 30, 2020 | -471.56% |
| Mar 31, 2020 | 38.04% |